A5080405815- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Blood groups and transfusion
- Animal Virus Infections Studies
- Glycosylation and Glycoproteins Research
- Respiratory viral infections research
- Immune responses and vaccinations
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Vaccine Coverage and Hesitancy
- Viral gastroenteritis research and epidemiology
- Neuroendocrine Tumor Research Advances
- Virus-based gene therapy research
The University of Melbourne
2022-2025
Peter Doherty Institute
2022-2025
High-risk groups, including Indigenous people, are at risk of severe COVID-19. Here we found that Australian First Nations peoples elicit effective immune responses to COVID-19 BNT162b2 vaccination, neutralizing antibodies, receptor-binding domain (RBD) SARS-CoV-2 spike-specific B cells, and CD4+ CD8+ T cells. In participants, RBD IgG antibody titers were correlated with body mass index negatively age. Reduced cells follicular helper in vaccinated participants chronic conditions (diabetes,...
Emerging SARS-CoV-2 variants, notably Omicron, continue to remain a formidable challenge worldwide public health. The receptor-binding domain (RBD) is hotspot for mutations, reflecting its critical role at the ACE2 interface during viral entry. Here, we comprehensively investigated impact of RBD including 5 variants concern (VOC) or interest-including Omicron (BA.2)-and 33 common point both on IgG recognition and ACE2-binding inhibition, as well FcγRIIa- FcγRIIIa-binding antibodies, in...
Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination is crucial to develop strategies for longer term immunity, especially against emerging viral variants. We profiled serial paired and plasma antibodies COVID-19 vaccinated only vaccinees (vaccinated, uninfected), COVID-19-recovered (recovered, vaccinated), individuals with breakthrough Delta or Omicron BA.2 infections infected). Saliva displayed improved antibody-neutralizing activity, Fcγ receptor (FcγR)...
Introduction Substantial population-level variation in vaccine-specific antibody responses has been observed following global coronavirus disease 2019 (COVID-19) vaccination efforts. Beyond the influence of clinical and demographic features, immunogenetic is suggested to underlie divergent serological COVID-19 distinct populations. Methods Immunoglobulin G1 (IgG1) allotypic markers (G1m) for 121 vaccinated healthy adults were genotyped via Sanger sequencing. Vaccine-specific IgG Fc gamma...
Abstract Objectives Bacille Calmette–Guérin (BCG) vaccination has off‐target effects on disease risk for unrelated infections and immune responses to vaccines. This study aimed determine the immunomodulatory of BCG vaccines against SARS‐CoV‐2. Methods Blood samples, from a subset 275 SARS‐CoV‐2‐naïve healthcare workers randomised (BCG group) or no (Control in BRACE trial, were collected before 28 days after primary course (two doses) ChAdOx1‐S (Oxford‐AstraZeneca) BNT162b2 (Pfizer‐BioNTech)...
Repeated mRNA COVID-19 vaccination increases spike-specific immunoglobulin G4 (IgG4) titers. Here, we characterized the influence of increased IgG4 titers on a range Fc-mediated responses. Elevated reduced binding to FcγRIIIa and decreased antibody-dependent cellular cytotoxicity. However, in individuals with lower total IgG, acted synergy other IgG subclasses improve FcγRI FcγRIIa consequently phagocytosis. Furthermore, this trend was more pronounced recent SARS-CoV-2 variants where induced...
Abstract Objectives Amino acid variations across more than 30 immunoglobulin (Ig) allotypes may introduce structural changes that influence recognition by anti‐Ig detection reagents, consequently confounding interpretation of antibody responses, particularly in genetically diverse cohorts. Here, we assessed a panel commercial monoclonal anti‐IgG1 clones for capacity to universally recognise two dominant IgG1 haplotypes (G1m‐1,3 and G1m1,17). Methods Four anti‐human were via ELISAs multiplex...
Summary Understanding mucosal antibody responses from SARS-CoV-2 infection and/or vaccination is crucial to develop strategies for longer term immunity, especially against emerging viral variants. We profiled serial paired and plasma antibodies from: COVID-19 vaccinated only vaccinees (vaccinated, uninfected), recovered (convalescent, vaccinated) individuals with breakthrough Delta or Omicron BA.2 infections infected). Saliva displayed improved neutralizing activity, FcγR engagement IgA...
Abstract Mucosal antibodies play a key role in protection against breakthrough COVID‐19 infections and emerging viral variants. Intramuscular adenovirus‐based vaccination (Vaxzevria) only weakly induces nasal IgG IgA responses, unless vaccinees have been previously infected. However, little is known about how Vaxzevria impacts the ability of mucosal to induce Fc particularly SARS‐CoV‐2 variants concern (VoCs). Here, we profiled paired (saliva, tears) plasma from vaccinated (uninfected,...
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains a formidable challenge to worldwide public health. receptor binding domain (RBD) the SARS-CoV-2 spike protein is hotspot for mutations, reflecting its critical role at ACE2 interface during viral entry. We comprehensively investigated impact RBD including 6 concern (VOC) or interest (Alpha, Beta, Gamma, Delta, Kappa and Omicron) 33 common point on IgG recognition, FcγR-engagement,...